J Biol Chem, Vol. 274, Issue 44, 31401-31409, October 29, 1999
An Internal Signal Sequence Mediates the Targeting and
Retention of the Human UDP-Glucuronosyltransferase 1A6 to the
Endoplasmic Reticulum*
Mohamed
Ouzzine
§,
Jacques
Magdalou
,
Brian
Burchell¶, and
Sylvie
Fournel-Gigleux
From
UMR CNRS 7561-Université Henri
Poincaré Nancy 1, Faculté de Médecine, BP 184, 54505 Vand
uvre-lès-Nancy, France and the ¶ Department of
Molecular and Cellular Pathology, Ninewells Hospital and Medical
School, University of Dundee, Dundee DD1 9SY, United Kingdom
 |
ABSTRACT |
The human UDP-glucuronosyltransferase isoform
UGT1A6 is predicted to be a type I transmembrane protein anchored in
the endoplasmic reticulum by a single C-terminal transmembrane domain,
followed by a short cytoplasmic tail. This topology is thought to be
established through the sequential action of a cleavable N-terminal
signal peptide and of a C-terminal stop transfer/anchor sequence. We found that the deletion of the signal peptide did not prevent membrane
targeting and insertion of this protein expressed in an in
vitro transcription/translation system or in yeast Pichia pastoris. Interestingly, the same results were obtained when the protein was depleted of both the signal peptide and the C-terminal transmembrane domain/cytoplasmic tail sequences, suggesting the presence of an internal topogenic element able to translocate and
retain UGT1A6 in the endoplasmic reticulum membrane in
vitro and in yeast cells. To identify such a sequence, the
insertion of several N-terminal deletion mutants of UGT1A6 into
microsomal membranes was investigated in vitro. The data
clearly showed that the deletion of the N-terminal end did not affect
endoplasmic reticulum targeting and retention until residues 140-240
were deleted. The signal-like activity of the 140-240 region was
demonstrated by the ability of this segment to confer endoplasmic
reticulum residency to the cytosolic green fluorescent protein
expressed in mammalian cells. Finally, we show that this novel
topogenic sequence can posttranslationally mediate the translocation of UGT1A6. This study provides the first evidence that the membrane assembly of the human UGT1A6 involves an internal signal retention sequence.
 |
INTRODUCTION |
Targeting and insertion of integral membrane proteins involve
characteristic topogenic sequences that act to initiate (signal peptide
sequence) and terminate (stop transfer sequence) translocation. In
mammalian cells, the N-terminal signal peptide generally targets the
protein to the endoplasmic reticulum
(ER)1 via a cotranslational
pathway by binding to the signal recognition particle, which then
interacts with its receptor and releases the signal sequence (1). A
second signal recognition event within the ER involving the Sec61
complex, the main constituent of a protein conducting channel, is then
required for the subsequent translocation of the nascent polypeptide
across the lipid bilayer (2). The elongating polypeptide is then
extruded through the membrane until a stop transfer sequence terminates
translocation and integrates laterally into the membrane. A number of
reports describing overlapping properties of signal sequences, signal anchors, and stop transfer sequences question the nature and
specificity of these topogenic sequences. The stop transfer sequence of
the IgM heavy chain (3) and the seventh transmembrane segment of band 3 of the erythrocyte anion exchanger (4) are able to initiate the
translocation process. Signal anchors can also act as signal sequences
as shown for cytochrome b5 (5) and for the yeast UBC6 transmembrane protein (6).
Single spanning membrane proteins that present a cleavable signal
peptide sequence usually have a type I topology with the N-terminal
part of the transmembrane domain exposed to the exterior of the
membrane and the C-terminal portion exposed to the cytoplasmic side
(N-exo/C-cyto). Examples of such bitopic membrane
proteins include the low density lipoprotein receptor (7), influenza virus hemagglutinin (8), and glycophorin A (9). In this study, we have
investigated the topogenic determinants that drive the membrane
assembly of the human UDP-glucuronosyltransferase (UGT) isoform UGT1A6,
an integral ER glycoprotein with a type I orientation. The UGT
superfamily consists of numerous isoforms catalyzing the addition of a
glycosidic residue, glucuronic acid, on to a wide variety of
hydrophobic acceptor substrates, i.e. small endogenous and
exogenous molecules, as well as complex glycolipids and glycoproteins
(10, 11). UGT1A6 is a major human UGT isoform playing an essential role
in the elimination of planar phenols, carcinogenic environmental
compounds, and therapeutic agents such as naftazone and paracetamol
(12-14).
Sequence alignment of more than 50 mammalian UGT cDNAs indicated
the presence of a hydrophobic N-terminal signal peptide sequence that
is cleaved during membrane insertion (15). Examination of the sequences
also suggested the presence of a single TMD of 17 amino acid residues
near the C-terminal end, followed by about 26 cytoplasmic residues
containing a di-lysine motif that could function as a ER
retrieval/retention signal (16, 17). Additional analysis of the
membrane topology of native UGTs in rat and human liver microsomes
using proteases and antibodies (18-20) or photoaffinity probes (21) as
well as studies performed on recombinant rat enzymes (22, 23)
suggested the picture of a transferase slightly exposed to the
cytoplasmic surface of the ER, joined by a single transmembrane region
to the bulk of the protein located inside the ER. However, the membrane
organization and the topological determinants of UGTs remain
hypothetical since no structural determination by x-ray crystallography
or nuclear magnetic resonance is yet available. This study represents
the beginning of a systematic effort to understand the structural
implications of the membrane-associated regions of UGTs. We previously
provided evidence that UGT1A6 with its signal peptide sequence deleted
remained integrally associated with the inner membrane of
Escherichia coli, when heterologously expressed in this host
cell (24).
To further address the mechanism by which UGT1A6 is targeted and
inserted into the ER membrane, we generated a series of truncations deleting individually or simultaneously the N- and C-terminal ends of
the protein. Using an efficient expression system in the yeast
Pichia pastoris together with in vitro expression
experiments in a reticulocyte lysate, we demonstrate the existence of a
previously unidentified internal topogenic sequence mediating the
translocation and retention of polypeptides across the ER membrane.
Moreover, we provide evidence for a posttranslational mechanism of
translocation of the full-length and truncated UGT1A6 polypeptides.
 |
EXPERIMENTAL PROCEDURES |
Materials--
[35S]Methionine was from Amersham
Pharmacia Biotech (Les Ulis, France). Bacterial and yeast culture media
were from Difco (Detroit, MI). Mammalian (Dulbecco's modified Eagle's
medium) cell culture medium was from Life Technologies, Inc.
(Cergy-Pontoise, France). Protein assay reagent was obtained from
Bio-Rad (Yvry sur Seine, France). Restriction enzymes, T4 DNA ligase,
RNAsinTM, pGEM-3Z, rabbit reticulocyte lysate, dog pancreas
microsomes, and competent E. coli JM109 cells were purchased
from Promega (Charbonnières, France). Prepro-
-factor mRNA
used as control in in vitro experiments was also provided by
Promega. The plasmid pEGFP-N1 for expression of protein fused to a red
shift variant of the green fluorescent protein of jellyfish was from
CLONTECH (Palo Alto, CA). The P. pastoris yeast expression system was from Invitrogen (Groningen,
The Netherlands). Vent DNA polymerase and endoglycosidase H
were provided by New England Biolabs (Hitchin, United Kingdom). Other
reagents including cycloheximide, proteinase K, methanol,
paraformaldehyde, fluorescein isothiocyanate (FITC)-conjugated anti-sheep immunoglobulins, rhodamine-conjugated anti-mouse
immunoglobulins, and anti-goat alkaline phosphatase-conjugated
immunoglobulins were purchased from Sigma (Saint Quentin Fallavier,
France). The glycosylation acceptor tripeptides
N-benzoyl-asparagine-asparagine-threonine-N-methylamide and
N-benzoyl-asparagine-alanine-serine-N-methylamide
were synthesized by Dr. G. Bloomberg (Recognition Center Peptide
Synthesis Facility, Bristol, United Kingdom) and used to inhibit
N-linked glycosylation, as described previously (25).
Plasmid Constructions--
Cloning and sequencing of full-length
UGT1A6 cDNA (GenBank accession no. M84130) have been reported
elsewhere (26). For in vitro expression of UGT1A6, the
corresponding cDNA was isolated from the eukaryotic expression
vector pcDNA1-UGT1A6 (27) and subcloned into the
EcoRI-XbaI sites of pGEM-3Z. UGT1A6 lacking the
signal peptide sequence was obtained by PCR amplification using a sense
primer comprising an EcoRI site, a Kozak sequence, and
nucleotides 79-102 corresponding to UGT1A6 coding region together with
an antisense primer comprising a XbaI site, a stop codon, and nucleotides 1593-1576. The PCR fragment was subcloned into the
EcoRI-XbaI sites of pGEM-3Z to generate
UGT1A6
SP. Constructs encoding polypeptides lacking the 26, 43, 68, 140, or 240 N-terminal amino acid residues as well as 43 C-terminal
residues (corresponding to the TMD/CT sequence) were generated by PCR
amplification using sense primers containing an EcoRI site,
a Kozak sequence, and nucleotides 79-102, 130-153, 205-228,
421-444, 721-744 corresponding to UGT1A6 coding region, respectively,
and an antisense primer comprising a XbaI site, a stop
codon, and nucleotides 1515-1498. The PCR products were individually
subcloned into the EcoRI-XbaI sites of pGEM-3Z to
generate UGT1A6
SP/TMD/CT, UGT1A6
-N43/TMD/CT, UGT1A6
-N68/TMD/CT, UGT1A6
-N140/TMD/CT, and UGT1A6
-N240/TMD/CT, respectively. The recombinant plasmids were then used for in
vitro transcription-translation in a rabbit reticulocyte lysate
using the T7 RNA polymerase.
To generate the UGT141-240/EGFP expression plasmid encoding a chimeric
protein between the 141-240 region of UGT1A6 and EGFP, a sense primer
comprising a HindIII site, a Kozak sequence, and nucleotides
421-441 corresponding to UGT1A6 coding region was used together with
an antisense primer comprising a BamHI site and nucleotides
720-702. The resulting amplified fragment was subcloned into the
HindIII-BamHI sites of the pEGFP-N1 vector in
frame with the EGFP coding sequence. The recombinant vector was used
for transient expression of the chimeric UGT141-240/EGFP protein in
HeLa 229 cells (European Collection of Cell Cultures, ECACC).
For expression in P. pastoris of wild-type and truncated
UGT1A6 mutants, the sequences coding for UGT1A6, UGT1A6
SP, and
UGT1A6
SP/TMD/CT were isolated from the corresponding pGEM-3Z
constructs and subcloned into the EcoRI-XbaI
sites of pPICZB. The corresponding expression vectors were named
pPICZ-UGT1A6, pPICZ-UGT1A6
SP, and pPICZ-UGT1A6
SP/TMD/CT. All
mutant clones were screened for Taq-introduced errors by
dideoxy sequencing (28).
In Vitro Protein Synthesis--
The in vitro
transcription-translation procedures were performed with T7 RNA
polymerase in the presence of rabbit reticulocyte lysate and
[35S]methionine, at 30 °C for 60 min using the
TNTTM coupled reticulocyte lysate kit from Promega. For
membrane translocation tests, dog pancreas microsomal membranes
(Promega) were added to the reaction mixture according to the
suggestions of the supplier. N-Glycosylation was prevented
by acceptor tripeptides (0.2 mM) added to the incubation
mixture before the microsomal membranes. For alkaline extraction, the
incubation mixture containing the microsomes was diluted two times in
buffer A (50 mM KOAc, 200 mM
Na2CO3, 20 mM triethanolamine, 1 mM Mg(OAc)2, pH 11.5) and kept in ice for 20 min to fracture microsomes and remove non-integral proteins. The
mixture was then layered over a 250-µl sucrose cushion (buffer B:
0.25 M sucrose, 50 mM triethanolamine, 140 mM KOAc, 2.5 mM Mg(OAc)2)
containing 100 mM Na2CO3, pH 11.5, and the membranes were pelleted at 100,000 × g in a
Sorvall RC M120 micro-ultracentrifuge for 45 min. The pellet was washed
with 25 µl of buffer B and suspended in sample loading buffer.
Supernatant proteins were precipitated with trichloroacetic acid (10%
(v/v)), and the samples were electrophoresed on 10% (w/v)
SDS-polyacrylamide gels (29). Protease sensitivity and topology of the
expressed polypeptide were analyzed using proteinase K as described
(30). The transcription-translation products were treated with 0.2 mg/ml proteinase K in the presence or absence of 0.1% (v/v) Triton
X-100 for 30 min on ice, and the reaction was stopped by addition of 1 mM phenylmethylsulfonyl fluoride. After 10 min, the samples
were heated at 100 °C in Laemmli sample buffer prior to SDS-PAGE
analysis. The following calibrated prestained SDS-PAGE standards
(Bio-Rad) were used: phosphorylase B, 107 kDa; bovine serum
albumin, 76 kDa; ovalbumin, 52 kDa; carbonic anhydrase, 36.8 kDa;
soybean trypsin inhibitor, 27.2 kDa; and lysozyme, 19 kDa. After
electrophoresis, gels were dried and exposed directly to Kodak Biomax
films for visualization.
Posttranslational Membrane Processing--
Following
linearization by XbaI, recombinant pGEM-3Z plasmids encoding
the full-length and truncated UGT polypeptides served as templates for
in vitro transcription by T7 RNA polymerase using mCAP RNA
capping kit (Stratagene, La Jolla, CA). The RNAs produced were
translated in vitro using the FlexiTM rabbit
reticulocyte lysate expression system (Promega). After translation for
30 min, 2 mM cycloheximide was added for 10 min to inhibit
further elongation. Translocation reactions were then initiated by
addition of dog pancreas microsomes and the incubation was continued
for 30 min at 30 °C. The same procedure was carried out using the
yeast prepro-
-factor mRNA as a control.
Heterologous Expression in the Yeast P. pastoris--
pPICZ-UGT1A6, pPICZ-UGT1A6
SP, and
pPICZ-UGT1A6
SP/TMD/CT were individually transformed into P. pastoris SMD 1168 (Invitrogen) by the lithium chloride method
according to the recommendations of the supplier. Transformants were
selected on YPD plates (1% yeast extract, 2% peptone, 2% dextrose)
containing 100 µg/ml Zeocin. The cells were grown in BMGY medium (1%
yeast extract, 2% peptone, 100 mM potassium phosphate, pH
6.0, 1.34% yeast nitrogen base, and 1% glycerol). Expression was
induced in a buffered BMGM medium (BMGY with 1% glycerol replaced by
2% methanol) and carried out for 48 h at 30 °C in a rotary
shaker (200 rpm).
Subcellular Fractionation and Protein Analysis of Recombinant
Yeast Cells--
Cells were harvested after 48 h of induction,
washed once, and suspended in cold breaking buffer (50 mM
sodium phosphate, pH 7.4, 1 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, and 5% glycerol). The cells were then
broken by vortexing with glass beads. The resulting homogenate was
centrifuged at 5,000 × g for 15 min, and the
supernatant was centrifuged at 12,000 × g for 20 min.
Membranes were then pelleted from the supernatant for 1 h at
100,000 × g at 4 °C. The pellet fraction was
resuspended by Dounce homogenization in sucrose-Hepes buffer (0.25 M sucrose, 5 mM Hepes, pH 7.4). Alkaline
extraction was carried out as described above. For high salt
extraction, membranes were incubated in buffer (50 mM
triethanolamine, 140 mM KOAc, 2.5 mM
Mg(OAc)2, 1 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, 1 M NaCl, pH 7.4) at 4 °C for 20 min, then layered over a 250-µl sucrose cushion (0.25 M sucrose, 50 mM triethanolamine, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 M NaCl, pH 7.4) and fractionated by centrifugation at
100,000 × g to yield pellet and soluble fractions. For
endoglycosidase H digestion, microsomal membranes were denatured in
0.5% SDS, 1%
-mercaptoethanol at 100 °C for 10 min and then
incubated with endoglycosidase H in 50 mM sodium citrate,
pH 5.5, buffer containing Complete MiniTM protease
inhibitors (Roche Molecular Biochemicals, Meylan, France) at 37 °C
for 1 h, according to the recommendations of the supplier (New
England Biolabs).
Protein concentration was evaluated by the method of Bradford (31).
SDS-PAGE (29) and immunoblot analysis were performed using anti-UGT1A6
antibodies and alkaline phosphatase-conjugated secondary antibodies as
described previously (27).
Immunofluorescence and Fluorescence Microscopy--
HeLa cells
were replated in 30-mm diameter wells on coverslips 1 day before
transfection with the pUGT141-240/EGFP plasmid using
ExgenTM as transfecting reagent (Euromedex,
Souffelweyersheim, France) and fixed after 24 h of culture with
3% paraformaldehyde (w/v) in PBS. Cells were permeabilized with 0.1%
(w/v) Triton X-100/PBS, followed by blocking with 0.2% gelatin/PBS
(w/v). Permeabilized cells were then incubated for 1 h with
monoclonal anti-calnexin antibodies (Affinity Bioreagents, Golden, CO),
washed in PBS, and incubated for 20 min with rhodamine-conjugated
secondary antibodies (32). Finally, cells were washed in PBS and
mounted on microscope slides using mounting medium (Sigma). Microscopic
observations were performed using a Zeiss Axiophot microscope with a
100× objective. Kodak Ektachrome 400 film was used for photography.
 |
RESULTS |
The N-terminal Signal Peptide Sequence Is Not Required for Membrane
Targeting and Integration of UGT1A6--
To study the process of
UGT1A6 targeting and insertion into the microsomal membranes, we
employed an in vitro transcription-translation expression
system using in the first instance two constructs. One of these
directed the synthesis of the full-length UGT1A6 precursor, and the
other was an engineered mutant, UGT1A6
SP, lacking 26 N-terminal
amino acids (the entire signal peptide sequence). A schematic
representation of the constructs appears in Fig.
1A. The insertion of the
polypeptides in dog pancreas microsomes was first characterized by
their glycosylation pattern and resistance to alkaline treatment. The
in vitro expression of UGT1A6 cDNA yielded a polypeptide
of about 54 kDa (Fig. 1B, lane a)
corresponding to the expected apparent molecular mass of the precursor,
as evaluated by comparison with calibrated molecular masses of
prestained SDS-PAGE standards. In the presence of microsomal membranes,
polypeptide bands exhibiting a slower mobility on gel electrophoresis
(55-56 kDa, Fig. 1B, lane c) were
observed. This increase of apparent molecular mass was consistent with
the cleavage of the signal peptide followed by
N-asparagine-linked glycosylation, previously described for
this UGT isoform (26). In the presence of acceptor tripeptides that are
competitive inhibitors of asparagine-linked glycosylation, a single
polypeptide band of 52 kDa was generated, which corresponds to the
mature unglycosylated form of UGT1A6 resulting from the cleavage of the
signal peptide sequence (Fig. 1B, compare lane
e to lanes a and c). In the
case of UGT1A6
SP, a polypeptide of about 52 kDa was produced in the
absence of microsomal membranes (Fig. 1B, lane
b), which was, as expected, about 2 kDa shorter than the
product of the wild-type cDNA expressed in the same conditions.
Interestingly, addition of microsomes to the transcription-translation
incubation mixture resulted in the appearance of higher molecular mass
species (Fig. 1B, lane d) that was
prevented by addition of glycosylation inhibitory tripeptides (Fig.
1B, lane f). These results indicate
that the deletion mutant, like the precursor form, was translocated and
N-glycosylated in the lumen of the ER. A high concentration
of a strong base is classically used to test the integration of
proteins into the membrane. Such treatment extracts only peripheral
membrane and secretory proteins but not integral membrane-bound
proteins. Both the wild-type UGT1A6 and the form lacking the signal
peptide sequence were found to be tightly integrated into the lipid
bilayer of microsomal membranes with the majority of the polypeptides
recovered in the pellet fraction (Fig. 1B, lanes
i and j). Fig. 1B (lanes
g and h) shows that, indeed, only small amounts
of protein could be detected in the supernatant. As a positive control,
the yeast prepro-
-factor expressed in the presence of microsomes was
processed and glycosylated to produce a 30-kDa polypeptide. This
secreted protein was effectively removed from the membrane pellet, when
subjected to alkaline treatment (Fig. 1B, lanes
k and l). The results of this set of experiments (glycosylation of newly synthesized chains and resistance to alkaline extraction) showed that UGT1A6, despite the lack of its N-terminal cleavable signal peptide, was translocated and integrated into the ER
membrane as the wild-type protein.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 1.
Deletion of the signal peptide does not
prevent membrane targeting and translocation of UGT1A6.
A, schematic linear representation of UGT1A6 precursor and
mature forms. The empty box represents the
predicted N-terminal signal peptide (SP) sequence and the
hatched box the C-terminal transmembrane domain
(TMD) followed by the cytoplasmic tail (CT). The
branched symbols are potential
oligosaccharide-linked asparagine-glycosylation sites. B,
full-length and truncated cDNAs were transcribed and translated
in vitro in the absence (lanes a and
b) or in the presence of dog pancreas microsomes (all
other lanes). The 35S-radiolabeled products were
analyzed by SDS-PAGE and subjected to autoradiography. Acceptor
tripeptides were used as inhibitors of N-linked
glycosylation (lanes e and f).
Microsomal membranes were subjected to carbonate extraction and
fractionated by centrifugation on a sucrose cushion to yield pellet
(P, lanes i, j, and
l) and supernatant (S, lanes
g, h, and k) fractions. Yeast
prepro- -factor (lanes k and l) is
shown as control of extractable soluble protein. C, Western
blot analysis of UGT1A6 expressed in the yeast P. pastoris.
Lane a shows whole cell extract. The microsomal
fraction (lane f) was separated into
alkaline-extracted supernatant (S, lane
b) and membrane pellet (P, lane
c) or into high salt-extracted supernatant (lane
b) and membrane pellet (lane f).
Sensitivity to endoglycosidase H digestion was analyzed in the
microsomal fraction (lane g). D,
Western blot analysis of UGT1A6 SP expressed in the yeast P. pastoris. Lanes a and b show total cell
extracts of yeast expressing UGT1A6 (shown for comparison) and
UGT1A6 SP, respectively. The microsomal fraction was separated into
alkaline-extracted supernatant (S, lane
c) and membrane pellet (P, lane
d) or into high salt-extracted supernatant (S,
lane e) and membrane pellet (P,
lane f). Sensitivity to endoglycosidase H
digestion was analyzed in the microsomal fraction (lane
g).
|
|
The in vitro targeting and translocation of UGT1A6 deprived
of its natural signal peptide prompted us to further investigate ER
targeting in vivo. A yeast P. pastoris expression
system was developed to analyze the topogenic elements mediating
membrane insertion of UGT1A6 in vivo. After subcloning both
full-length and truncated UGT1A6 cDNA into the expression vector
pPICZB, the resultant recombinant plasmids were individually
transformed in the methyltrophic yeast strain P. pastoris.
Upon methanol induction, expression of both wild-type UGT1A6 and mutant
lacking the signal peptide sequence was successfully achieved. Western
blot analysis of whole cell extracts showed that the recombinant
wild-type UGT1A6 migrated on SDS-polyacrylamide gel as a polypeptide
band of approximately 55-56 kDa (Fig. 1C, lane
a). Subfractionation experiments showed that, as expected,
the protein was associated with the microsomal membranes and was
resistant to alkaline (Fig. 1C, lanes
b and c) and to high salt extraction (Fig.
1C, lanes d and e).
Treatment of the microsomal fraction with endoglycosidase H under
denaturating conditions resulted in the appearance of a lower molecular
mass band (Fig. 1C, compare lane g to
lane f), indicating that UGT1A6 was translocated
and retained in the ER of recombinant yeast cells. Interestingly,
Western blot analysis performed on recombinant yeast cell extracts
expressing UGT1A6
SP (Fig. 1D) showed that this
polypeptide exhibited the same apparent molecular mass as the wild-type
(55-56 kDa), suggesting that despite the absence of signal sequence,
the protein was also targeted and translocated across the ER (Fig.
1D, lanes a and b). Upon
sodium carbonate (Fig. 1D, lanes c and
d) or high salt (Fig. 1D, lanes
e and f) extraction, the polypeptide remained
associated with the microsomal fraction, indicating that the protein
was integrated into the membranes. Moreover, the protein was sensitive
to endoglycosidase H digestion (decrease of apparent molecular mass of
2 kDa, Fig. 1D, lane g) similarly to
the wild-type protein suggesting a compartmentalization restricted to
the ER. To further assess the intracellular localization of wild-type
and mutant UGT1A6 expressed in yeast cells, immunofluorescence microscopy studies were carried out. The wild-type UGT1A6 exhibited a
typical ER staining pattern (data not shown). The same ER staining pattern was observed in P. pastoris expressing UGT1A6
SP,
confirming that the deletion of the UGT1A6 signal peptide did not
prevent targeting and ER residency of the protein (data not shown).
Based both on in vitro and in vivo experiments,
these results provide evidence that the absence of the signal peptide
does not preclude ER targeting, translocation, and retention of UGT1A6.
Evidence for an Internal Signal-like Sequence--
Members of the
UGT family present a hydrophobic stretch of 17 amino acids at the C
terminus followed by a positively charged tail of about 26 amino acids,
thought to be important for membrane integration and ER retention (16,
17). Therefore, we analyzed the consequences of the deletion of this
region by creating a mutant lacking 43 C-terminal amino acid residues
as well as the N-terminal leader peptide (UGT1A6
SP/TMD/CT
represented in Fig. 2A).
In vitro transcription-translation showed that in the
absence of microsomal membranes, the UGT1A6
SP/TMD/CT construct
yielded a polypeptide of the expected size (about 48-49 kDa) (Fig.
2B, lane b). Expression of UGT1A6
full-length cDNA in the same conditions is shown for comparison
(Fig. 2B, lane a). When microsomal
membranes were added, polypeptide bands of higher apparent molecular
mass (about 49-51 kDa) were produced (Fig. 2B,
lane c). In the presence of competitive
glycosylation inhibitor tripeptides, the expressed polypeptide
comigrated with the unglycosylated product formed when the membranes
were omitted (Fig. 2B, compare lane d
to lane b), indicating that UGT1A6 lacking both
signal peptide and TMD/CT sequences was translocated and glycosylated
in the lumen of the ER. Alkaline treatment (also shown in Fig.
2B) demonstrates that the majority of the polypeptide was
associated with the membrane fraction (compare lane
f to lane e).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 2.
UGT1A6 depleted of both the N-terminal signal
peptide and the C-terminal TMD/CT domain is translocated and retained
in the ER. A, schematic representation of full-length
UGT1A6 and of the truncated polypeptide UGT1A6 SP/TMD/CT.
B, in vitro transcription-translation of
UGT1A6 SP/TMD/CT. UGT1A6 SP/TMD/CT was expressed in the absence of
dog pancreas microsomes (lane b) compared with
UGT1A6 (lane a) or in the presence of dog
pancreas microsomes (lane c) and of
N-glycosylation tripeptide inhibitors (lane
d). Microsomal membranes were alkaline-extracted and
fractionated on a sucrose cushion into supernatant (S,
lane e) and membrane pellet fractions
(P, lane f). C, Western
blot analysis of UGT1A6 SP/TMD/CT expression in the yeast P. pastoris. Whole cell extracts of yeast expressing UGT1A6 and
UGT1A6 SP (shown for comparison; lanes a and
b, respectively) and of yeast expressing
UGT1A6 SP/TMD/CT (lane c) were analyzed using
anti-UGT1A6 antibodies. Microsomal membranes of recombinant yeasts were
alkaline- or high salt-extracted and fractionated on sucrose cushions
into supernatant (S, lanes d and
f, respectively) and pellet (P, lanes
e and g, respectively). Sensitivity to
endoglycosidase H digestion was analyzed in the microsomal fraction
(lane h).
|
|
The above construct was also successfully expressed in the yeast
P. pastoris, allowing the in vivo examination of
the subcellular targeting of the N- and C-terminal truncated UGT1A6
polypeptide (Fig. 2C). In whole yeast cell extracts, an
immunoreactive protein about 3-4 kDa smaller than UGT1A6 and
UGT1A6
SP was detected (Fig. 2C, lane
c compared with lanes a and
b). In addition, similarly to the latter polypeptides,
strong base (Fig. 2C, lanes d and e) and high salt extraction (Fig. 2C,
lanes f and g) did not release UGT1A6
SP/TMD/CT protein from the microsomal membranes, as the majority of the protein was recovered in the pellet. This result indicates that, despite the absence of the predicted transmembrane domain, UGT1A6 remains an integral membrane-bound protein. Sensitivity to endoglycosidase H, as evidenced by a 2-kDa decrease of apparent molecular mass, indicated that UGT1A6
SP/TMD/CT was
N-glycosylated and retained in the ER of yeast cells (Fig.
2C, lane h).
Finally, to analyze the membrane orientation of UGT1A6 expressed as
wild-type or truncated polypeptides, we employed a "protease protection assay" as described by Connolly et al. (30).
The cDNAs encoding the UGT1A6 precursor, UGT1A6 lacking the
N-terminal signal peptide only or lacking both the signal peptide and
the C-terminal TMD/CT sequences (represented in Fig.
3A), were expressed in
vitro. Fig. 3B shows the effect of proteinase K on the
transcription-translation products. It is clear that UGT1A6,
UGT1A6
SP, and UGT1A6
SP/TMD/CT polypeptides were
protease-protected, when synthesized in the presence of membranes (Fig.
3B, lanes a, b, and c,
respectively), whereas, in the absence of microsomes, the polypeptides
were completely degraded (Fig. 3B, lanes d, e,
and f, respectively) as well as in the presence
of detergent (data not shown). These results suggested that the
products of the truncated constructs have probably acquired a lumenal
orientation similarly to that of the wild-type protein. This set of
experiments provided evidence that the absence of the N-terminal signal
peptide and of the C-terminal TMD/CT sequence did not prevent ER
targeting, translocation, and membrane integration of UGT1A6 either
in vitro or in yeast cells. The most likely explanation of
these observations is the presence of internal topogenic information capable of mediating the membrane targeting and retention process.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 3.
Full-length and truncated UGT1A6 polypeptides
are protease-protected. A, schematic drawing of UGT1A6
polypeptides encoded by the full-length and truncated cDNAs.
B, the cDNAs were transcribed and translated in
vitro in the presence (+) or absence ( ) of microsomal membranes
and treated with proteinase K as described under "Experimental
Procedures." Lanes a and d, UGT1A6;
lanes b and e, UGT1A6 SP;
lanes c and f, UGT1A6 SP/TMD/CT.
Radiolabeled polypeptides were separated by SDS-PAGE and subjected to
autoradiography.
|
|
Identification of the Region Containing the Internal Signal Peptide
Sequence--
To find out the position of the putative signal-like
region, serial N-terminal deletions of UGT1A6 were generated to
successively remove computer-predicted hydrophobic stretches (33).
Mutants lacking the coding sequence for 43, 68, 140, and 240 N-terminal amino acid residues and the C-terminal TMD/CT region were generated (Fig. 4A) and used for
in vitro transcription-translation in the presence or
absence of dog pancreas microsomes.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 4.
Deletion of 240 N-terminal residues but not
of 140 residues, in the absence of TMD/CT region, prevents the
translocation of UGT1A6. A, schematic illustration of
UGT1A6 polypeptides deleted from N- and C-terminal ends. B,
transcription-translation of UGT1A6 -N140/TMD/CT and
UGT1A6 -N240/TMD/CT was performed in vitro in the absence
(lanes a and f, respectively) or
presence (other lanes) of dog pancreas
microsomes. N-Glycosylation of UGT1A6 -N140/TMD/CT and
UGT1A6 -N240/TMD/CT was tested by the addition of tripeptide
acceptors during in vitro synthesis (lanes
d and i, respectively). Following expression of
UGT1A6 -N140/TMD/CT or UGT1A6 -N240/TMD/CT, microsomal membranes
were subjected to alkaline extraction and fractionated by
centrifugation on a sucrose cushion to yield membrane-bound
(P, lanes b and g,
respectively) and supernatant (S, lanes
c and h, respectively) fractions.
|
|
The deletion of 43 and 68 N-terminal amino acid residues and of the
C-terminal TMD/CT region of UGT1A6 did not modify the glycosylation
pattern nor the resistance to alkaline treatment of the protein (data
not shown). The consequence of further deletion, i.e. 140 N-terminal amino acid residues after expression in a cell-free system,
is illustrated in Fig. 4B. The in vitro
expression of the mutant UGT1A6
-N140TMD/CT produced a polypeptide of
about 35 kDa (Fig. 4B, lane a). When
the expression system was supplemented with microsomes, higher
molecular mass bands of 35-37 kDa were produced (Fig. 4B,
lane e). This gel migration shift was reverted by
the presence of glycosylation inhibitor tripeptides (Fig.
4B, lane d), suggesting that the
UGT1A6
-N140/TMD/CT polypeptide was translocated across the ER
membrane. Resistance to alkaline extraction further demonstrated that
it was integrated into the lipid bilayer (Fig. 4B,
lanes b and c). By contrast, the
in vitro expression of the UGT1A6
-N240/TMD/CT mutant
resulted in the production of polypeptide bands of an identical size
when transcribed and translated in the presence or in the absence of
membranes (Fig. 4B, lanes f and
j), indicating that glycosylation did not take place and providing evidence that the removal of 100 more amino acid residues (residue 141-240 region of UGT1A6) destroyed the capacity of UGT1A6 to
cross the ER membrane. This was supported by the absence of an effect
of acceptor tripeptides on the electrophoretic mobility of the
expressed polypeptide (Fig. 4B, lane
i). As expected, the majority of the expressed
unglycosylated polypeptide was found in the supernatant following
sodium carbonate extraction and 100,000 × g
centrifugation (Fig. 4B, compare lanes
h and g). These findings strongly support the
presence of an internal topogenic element located in the 141-240
region of UGT1A6 able to target and to retain UGT1A6 to the ER membrane.
UGT1A6 Inserts into Microsomal Membranes at the Co- and
Posttranslational Levels--
We next examined a possible
posttranslational translocation mechanism of UGT1A6. For this purpose,
translation of mRNAs encoding full-length and truncated UGT1A6
mutants was completed in a rabbit reticulocyte lysate. Further protein
elongation was blocked by cycloheximide prior to the addition of
microsomal membranes. The results clearly show that UGT1A6 and
UGT1A6
SP as well as UGT1A6
SP/TMD/CT and UGT1A6
-N140/TMD/CT
were efficiently translocated and glycosylated when expressed
posttranslationally, as evidenced by the presence of slower migrating
bands compared with their counterparts expressed in the absence of
membranes (Fig. 5A, compare
lanes a and b, c and
d, e and f, and g and h).
As control, yeast prepro-
-factor synthesized in identical conditions
to UGT polypeptides (Fig. 5B, lane i)
exhibited no posttranslational translocation (Fig. 5B,
lane j), but was efficiently translocated and
glycosylated when the membranes were present cotranslationally (Fig.
5B, lane k), in agreement with
previous reports (34). Altogether, these data indicate that the UGT1A6
preprotein and truncation mutants can be targeted and inserted into
membranes not only at co- but also at posttranslational level.

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 5.
A, wild-type and truncated UGT1A6 mutant
translocation can occur posttranslationally. The cDNAs constructs
served as templates for in vitro transcription using T7 RNA
polymerase. RNA products were translated as described under
"Experimental Procedures." Polypeptide chain elongation was
arrested by addition of cycloheximide and translocation was then
initiated by addition of microsomal membranes. Lanes
a and b correspond to UGT1A6, lanes
c and d to UGT1A6 SP, lanes
e and f to UGT1A6 SP/TMD/CT, lanes
g and h to UGT1A6 -N140/TMD/CT translation
products analyzed before ( ) or after (+) the addition of dog pancreas
microsomes, respectively. As control, the yeast prepro- -factor was
expressed in vitro (lane i) and
translocated posttranslationally (lane j) or
cotranslationally (lane k).
|
|
The 141-240 UGT1A6 Domain Addresses the EGFP Reporter Protein to
the ER of Mammalian Cells--
From the in vitro studies
reported above, it was likely that the 141-240 region of UGT1A6
contains an internal signal-like sequence capable of membrane targeting
and translocation. To assess the signal activity of this region
in vivo, we tested its ability to target the fluorescent
reporter EGFP protein to the ER. The chimeric and the native EGFP
cDNAs were transiently expressed in HeLa cells. We examined the
intracellular localization of the expressed proteins by direct
fluorescence microscopy 24 h after transfection. The native EGFP
expression resulted in an homogeneous staining characteristic of a
cytoplasmic location (Fig.
6A). Interestingly, cells
expressing the UGT141-240/EGFP chimera presented a dramatically different fluorescent staining pattern consistent with an ER
localization (Fig. 6B). This staining pattern
overlapped with that of calnexin, a typical ER marker (Fig.
6C). These observations provide strong evidence that the
141-240 region of UGT1A6 contains a targeting and retention signal
able to confer ER residency to the cytoplasmic EGFP reporter protein in
mammalian cells.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 6.
The 141-240 UGT1A6 domain addresses the EGFP
reporter protein to the ER of mammalian cells. The 141-240 domain
of UGT1A6 containing the putative internal signal sequence was fused
upstream to the coding sequence of EGFP, and the native and chimeric
proteins were transiently expressed in HeLa cells. The localization of
EGFP (A) and of UGT141-240/EGFP (B) was assessed
by fluorescence microscopy 24 h after transfection. The
localization of UGT141-240/EGFP was compared with that of calnexin
stained with anti-calnexin antibodies and rhodamine-conjugated
secondary antibodies (C).
|
|
 |
DISCUSSION |
It has become clear over the past decade that selective
trafficking and compartmentalization of proteins throughout the cell requires the recognition of sorting determinants present in their primary structure (1, 35, 36). A significant finding from the present
study is that internal topogenic information contained within the
N-terminal half of UGT1A6 functions as an ER targeting and retention
signal, in addition to the predicted N-terminal cleavable signal
peptide sequence and C-terminal transmembrane anchor domain.
For eukaryotic proteins with a type I topology such as UGT1A6, the best
characterized insertion mechanism is the signal recognition particle-dependent pathway in which membrane targeting is
initiated cotranslationally by a signal peptide at the N terminus of
the nascent peptide. For these proteins, integration occurs via a complex multistep process ending with the release of the polypeptide into the lipid bilayer coincident with the completion of protein synthesis. A first important result of this study is that the deletion
of the N-terminal cleavable leader sequence of UGT1A6 does not prevent
targeting and ER insertion. The addition of carbohydrate as an
endogenous marker for peptides exposed to the lumen of the ER,
resistance to alkaline extraction and protease protection showed that
UGT1A6 lacking the signal peptide expressed in vitro is an
integral membrane-bound protein and that the N-glycosylation sites have achieved a lumenal orientation. We further investigated the
role of the signal peptide in vivo using, for the first
time, the yeast P. pastoris expression system. High levels
of expression enabled us to analyze the fate of the mutant lacking the
signal peptide compared with the wild-type protein. Based on the same criteria as for in vitro analysis, we found that ER
targeting of UGT1A6 in yeast cells did not require the N-terminal
cleavable signal peptide. Both wild-type and mutant proteins were
integral membrane-bound polypeptides, as evidenced by resistance to
alkaline and high salt extraction. Moreover, the protein was sensitive to endoglycosidase H, indicating that despite the lack of the N-terminal cleavable signal peptide, the predicted intralumenal domain
of UGT1A6 was translocated across the yeast ER membrane. Immunofluorescence observation confirmed that UGT1A6
SP was localized in the ER of yeast cells, as the wild-type protein. Altogether, within
the resolution of the in vitro and in vivo assays
performed in this study, ER targeting, translocation, and retention of
UGT1A6 were not prevented by the absence of the N-terminal signal
peptide sequence. The ability of proteins deprived of their natural
signal peptide to be targeted and translocated across the ER is unusual but not unprecedented. It was reported that the cleavable signal peptide of the yeast secreted carboxypeptidase Y (37) and acid phosphatase (38) could be entirely removed without abolishing the
ability of these proteins to be translocated and glycosylated in the
ER. A related observation was also recently described for the human
sodium-calcium exchanger, an integral plasma membrane polytopic protein
containing a N-terminal cleavable leader sequence (39). The authors
showed that, despite the lack of signal peptide sequence, the
Na+-Ca2+ exchanger was addressed to its normal
subcellular localization.
It has been proposed that, when the wild-type N-terminal signal peptide
is deleted or made dysfunctional, hydrophobic internal segments can
promote the translocation of the protein (40). This prompted us to
search for some structural features other than the typical N-terminal
cleavable signal peptide involved in ER targeting and assembly of
UGT1A6. UGT1A6 is predicted by hydropathy analysis to feature a
C-terminal membrane spanning domain, which may act as a targeting
retention signal in the absence of the N-terminal signal peptide. The
finding that a UGT1A6 polypeptide lacking both the N-terminal leader
peptide and the C-terminal TMD/CT domain was targeted into the ER when
expressed either in vitro or in yeast cells was a crucial
argument for the presence of an internal signal-like sequence.
Furthermore, the observation that this N- and C-terminal truncated
protein was tightly associated with the microsomal membranes showed
that some region of UGT1A6 not only acts as a signal sequence but
also as an ER retention determinant. Moreover, the sensitivity of
UGT1A6
SP/TMD/CT to endoglycosidase H deglycosylation clearly shows
that translocation of the lumenally exposed domain of UGT1A6 was
achieved. These data also suggest that the truncated polypeptide has
not moved past an ER/pre-Golgi compartment. Since computer-based
secondary structure prediction identifies only the N-terminal cleavable signal peptide and C-terminal TMD/CT region as topogenic elements, the
membrane targeting and association of UGT1A6
SP/TMD/CT, in both
expression systems used, was unexpected. Interestingly, computer based
analysis predicted some buried
-helices in UGT1A6 as well as in
other members of the UGT1 family (41). Although these domains are not,
in theory, long enough to span the membrane, they could interact with
the lipid bilayer via hydrophobic interactions. Resistance to protease
treatment carried out in this study and by others (18, 20) does not
favor the hypothesis of the presence of other membrane-spanning
segments than the C-terminal TMD. The observation that the interactions
of UGT1A6
SP/TMD/CT with the membrane cannot be disrupted by standard
extraction techniques utilizing high pH and high salt concentration
confirms that it is an integral membrane-bound polypeptide. In
agreement with our results, Meech and Mackenzie (42) found that the rat
liver UGT2B1 isoform remained resident in the ER of recombinant
mammalian cells in the absence of a cytosolic tail and transmembrane
domain. It is noteworthy that the hydrophobic transmembrane helix is
not the only possible membrane binding motif. Determination of the crystal structure of the prostaglandin H2 synthase has led to a model
of membrane insertion on the lumenal face of the ER mediated by a motif
of short
-helices, which do not span the ER membrane (43). Based on
crystal structure analysis, similar membrane-binding characteristics
have also been reported for a squalene cyclase from
Alicyclobacillus acidocaldarius (44).
N-terminal deletion analysis performed in an in vitro
expression system allowed us to localize the targeting-retention signal within region 141-240 of UGT1A6. Indeed, addition of
N-linked carbohydrates and resistance to alkaline extraction
were abolished when 240 N-terminal residues were deleted. The ability
of the 141-240 domain to confer ER residency to the soluble EGFP
reporter protein unequivocally established the signal and retention
function of this sequence. The highly conserved secondary structural
features of this region supports the notion that it has a specific role in the biogenesis of UGTs. It has been suggested that the need for an
internal signal sequence arises from the entire protein being too large
to be translocated across the membrane and hence the requirement to
re-engage the translocation channel (4). Such an internal signal may be
critical in the case of UGTs to allow the localization of the majority
of the polypeptide on the lumenal face of the ER.
It must be emphasized that aglycone substrates of UGTs are liphophilic
molecules. It is accepted that they reach their binding site localized
in the N-terminal half of the proteins by passive diffusion through the
lipid bilayer (45). An attractive hypothesis is that the membrane
interaction conferred by the 141-240 region may provide a hydrophobic
path from the membrane interior to the catalytic site. This mode of
membrane interaction may also explain why lipids are important in the
functional integrity of these phospholipid-dependent enzymes.
Translocation of type I transmembrane proteins with a N-cleavable
signal peptide such as UGTs across the ER membrane involves the
cotranslational delivery of the nascent chain. Surprisingly, we found
that the UGT1A6 precursor as well as the N- and C-terminal mutants can
insert into the microsomal membranes posttranslationally. The existence
of a posttranslational mode of translocation has been clearly
demonstrated in yeast (46, 47) but is far less documented in higher
eukaryotic species (48). It has been suggested in some cases such as
type IV or C-anchored transmembrane proteins, UCB6 (6), and Bcl-2
proto-oncogenic protein (49). These proteins are characterized by
hydrophobic segments close to or at their C termini, precluding
cotranslational membrane insertion (6).
From the results of this study, we propose that UGT1A6 membrane
assembly is mediated by an internal ER targeting and retention signal,
presumably acting through a posttranslational pathway, in addition to
the known predicted topogenic determinants, i.e. the
N-terminal cleavable signal sequence and the C-terminal TMD/CT domain.
It is noteworthy that the involvement of a combination of topogenic
elements for the achievement of correct subcellular localization is
described for a growing number of membrane proteins. A polytopic
membrane protein, the cystic fibrosis transmembrane conductance
regulator, has been convincingly demonstrated to acquire its N terminus
topology through the arrangement of the cotranslational action of the
first transmembrane domain and the posttranslational action of the
second transmembrane domain (50). In the same manner, the membrane
integration of the gap junctional protein connexin 26 was shown to
occur posttranslationally possibly involving an internal signal
sequence (51).
We bring here convincing evidence that the membrane assembly of the
human UGT1A6 in the ER membrane involves a previously unidentified
internal signal and retention sequence in addition to the N-terminal
cleavable signal peptide and stop-transfer domain. Our results support
the idea that this topogenic element not only mediates targeting and
translocation of UGT1A6 but also features a characteristic membrane
association domain likely to be of major importance in the structure
and function of this protein.
 |
ACKNOWLEDGEMENT |
We thank Dr. D. J. S. Hulmes for
critical reading of the manuscript and helpful discussions.
 |
FOOTNOTES |
*
This work was supported by grants from CNRS, Région
Lorraine, EC Biomed 2 Project BMH-97-2621 and by a Wellcome Trust
collaborative research grant between the Université Henri
Poincaré Nancy and University of Dundee.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed. Tel.: 33-3-83-59-27-49;
Fax: 33-3-83-59-26-21; E-mail: ouzzine@pharmaco-med.u-nancy.fr.
 |
ABBREVIATIONS |
The abbreviations used are:
ER, endoplasmic
reticulum;
FITC, fluorescein isothiocyanate;
EGFP, enhanced green
fluorescent protein;
PBS, phosphate buffer saline;
PCR, polymerase
chain reaction;
PAGE, polyacrylamide gel electrophoresis;
TMD/CT, transmembrane domain/cytoplasmic tail;
UGT, UDP-glucuronosyltransferase..
 |
REFERENCES |
| 1.
|
Blobel, G.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
79,
3111-3115
|
| 2.
|
Jungnickel, B.,
and Rapoport, T. A.
(1995)
Cell
82,
261-270[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Mize, N. K.,
Andrews, D. W.,
and Lingappa, V. R.
(1986)
Cell
47,
711-719[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Tam, L. Y.,
Loo, T. W.,
Clarke, D. M.,
and Reithmeier, R. A. F.
(1994)
J. Biol. Chem.
269,
32542-32550[Abstract/Free Full Text]
|
| 5.
|
Honsho, M.,
Mitoma, J.,
and Ito, A.
(1998)
J. Biol. Chem.
273,
20860-20866[Abstract/Free Full Text]
|
| 6.
|
Yang, M.,
Ellenberg, J.,
Bonifacino, J. S.,
and Weissman, A. M.
(1997)
J. Biol. Chem.
272,
1970-1975[Abstract/Free Full Text]
|
| 7.
|
Russell, D. W.,
Schneider, W. J.,
Yamamoto, T.,
Luskey, K. L.,
Brown, M. S.,
and Goldstein, J. E.
(1984)
Cell
37,
577-585[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Chao, C. C. K.,
Bird, P.,
Gething, M. J.,
and Sambrook, J.
(1987)
Mol. Cell. Biol.
7,
3842-3845[Abstract/Free Full Text]
|
| 9.
|
Oliver, J.,
Jungnickel, B., D., G.,
Rapoport, T.,
and High, S.
(1995)
FEBS Lett.
362,
126-130[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Dutton, G. J.
(ed)
(1980)
Glucuronidation of Drugs and Other Compounds
, CRC Press Inc., Boca Raton, FL
|
| 11.
|
Radominska, A.,
Little, J. M.,
Drake, R.,
Igari, Y.,
Fournel-Gigleux, S.,
Magdalou, J.,
Burchell, B.,
Elbein, A.,
Siest, G.,
and Lester, R.
(1993)
J. Biol. Chem.
268,
15127-15135[Abstract/Free Full Text]
|
| 12.
|
Fournel-Gigleux, S.,
Sutherland, L.,
Sabolovic, N.,
Burchell, B.,
and Siest, G.
(1991)
Mol. Pharmacol.
39,
177-183[Abstract]
|
| 13.
|
Herber, R.,
Hercelin, B.,
Van Cantfort, J.,
De Graeve, J.,
Fournel-Gigleux, S.,
Taguchi, T.,
and Magdalou, J.
(1995)
Drug Metab. Dispos.
23,
1305-1314[Abstract]
|
| 14.
|
Bock, K. W.,
Forster, A.,
Gschaidmeier, H.,
Brück, M.,
Münzel, P.,
Schareck, W.,
Fournel-Gigleux, S.,
and Burchell, B.
(1993)
Biochem. Pharmacol.
45,
1809-1814[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Mackenzie, P. I.,
Owens, I. S.,
Burchell, B.,
Bock, K. W.,
Bairoch, A.,
Belanger, A.,
Fournel-Gigleux, S.,
Green, M.,
Iyanagi, T.,
Lancet, D.,
Louisot, P.,
Magdalou, J.,
Chowdhury, J. R.,
Rotter, J. K.,
Schachter, H.,
Tephly, T. R.,
Tipton, K. F.,
Tukey, R. H.,
and Nebert, W.
(1997)
Pharmacogenetics
7,
255-269[Medline]
[Order article via Infotrieve]
|
| 16.
|
Jackson, M. R.,
Nilsson, T.,
and Peterson, P. A.
(1990)
EMBO J.
9,
3153-3162[Medline]
[Order article via Infotrieve]
|
| 17.
|
Jackson, M. R.,
Nilsson, T.,
and Peterson, P. A.
(1993)
J. Cell Biol.
121,
317-333[Abstract/Free Full Text]
|
| 18.
|
Shepherd, S. R. P.,
Baird, S. J.,
Hallinan, T.,
and Burchell, B.
(1989)
Biochem. J.
259,
617-620[Medline]
[Order article via Infotrieve]
|
| 19.
|
Pillot, T.,
Ouzzine, M.,
Fournel-Gigleux, S.,
Lafaurie, C.,
Radominska, A.,
Burchell, B.,
Siest, G.,
and Magdalou, J.
(1993)
J. Biol. Chem.
268,
25636-25642[Abstract/Free Full Text]
|
| 20.
|
Yokota, H.,
Yuasa, A.,
and Sato, R.
(1992)
J. Biol. Chem.
112,
192-196
|
| 21.
|
Drake, R.,
Igari, I.,
Lester, R.,
Elbein, A.,
and Radominska, A.
(1992)
J. Biol. Chem.
267,
11360-11365[Abstract/Free Full Text]
|
| 22.
|
Meech, R.,
Yogalingam, G.,
and Mackenzie, P.
(1996)
DNA Cell Biol.
15,
489-494[Medline]
[Order article via Infotrieve]
|
| 23.
|
Meech, R.,
and Mackenzie, P. I.
(1997)
J. Biol. Chem.
272,
26913-26917[Abstract/Free Full Text]
|
| 24.
|
Ouzzine, M.,
Fournel-Gigleux, S.,
Pillot, T.,
Burchell, B.,
Siest, G.,
and Magdalou, J.
(1994)
FEBS Lett.
339,
195-199[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
High, S.,
Flint, N.,
and Dobberstein, B.
(1991)
J. Cell Biol.
113,
25-34[Abstract/Free Full Text]
|
| 26.
|
Harding, D.,
Fournel-Gigleux, S.,
Jackson, M. R.,
and Burchell, B.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
8381-8385[Abstract/Free Full Text]
|
| 27.
|
Ouzzine, M.,
Pillot, T.,
Fournel-Gigleux, S.,
Burchell, B.,
Siest, G.,
and Magdalou, J.
(1994)
Arch. Biochem. Biophys.
310,
196-204[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Sanger, F.,
Nicklen, S.,
and Coulson, A. R.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
74,
5463-5467
|
| 29.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Connolly, T.,
Collins, P.,
and Gilmore, R.
(1989)
J. Cell Biol.
108,
299-307[Abstract/Free Full Text]
|
| 31.
|
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Rajagopalan, S.,
Xu, Y.,
and Brenner, M. B.
(1994)
Science
263,
387-389[Abstract/Free Full Text]
|
| 33.
|
Kyte, J.,
and Doolittle, R. F.
(1982)
J. Mol. Biol.
157,
105-132[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Garcia, P. D.,
and Walter, P.
(1988)
J. Cell Biol.
106,
1043-1048[Abstract/Free Full Text]
|
| 35.
|
Letourneur, F.,
and Klausner, R. D.
(1992)
Cell
69,
1143-1157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Pelham, H. R.
(1990)
Trends Biol. Sci.
15,
483-486
|
| 37.
|
Blachly-Dyson, E.,
and Stevens, T. H.
(1987)
J. Cell Biol.
104,
1183-1191[Abstract/Free Full Text]
|
| 38.
|
Silve, S.,
Monod, M.,
Hinnen, A.,
and Haguenauer-Tsapis, R.
(1987)
Mol. Cell. Biol.
7,
3306-3314[Abstract/Free Full Text]
|
| 39.
|
Loo, T. W.,
Ho, C.,
and Clarke, D. M.
(1995)
J. Biol. Chem.
270,
19345-19350[Abstract/Free Full Text]
|
| 40.
|
Chen, H.,
and Kendall, D. A.
(1995)
J. Biol. Chem.
270,
14115-14122[Abstract/Free Full Text]
|
| 41.
|
Ciotti, M.,
Cho, J. W.,
and Owens, I. S.
(1998)
Biochemistry
37,
11018-11025[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Meech, R.,
and Mackenzie, P. I.
(1998)
Arch. Biochem. Biophys.
356,
77-85[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Picot, D.,
Loll, P. J.,
and Garavito, R. M.
(1994)
Nature
367,
243-249[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Wendt, K. U.
(1997)
Science
277,
1811-1815[Abstract/Free Full Text]
|
| 45.
|
Zucker, S. D.,
Goessling, W.,
Zeidel, M. L.,
and Gollan, J. L.
(1994)
J. Biol. Chem.
269,
19262-19270[Abstract/Free Full Text]
|
| 46.
|
Corsi, A. K.,
and Schekman, R.
(1996)
J. Biol. Chem.
271,
30299-30302[Free Full Text]
|
| 47.
|
Ng, D. T. W.,
Brown, J. D.,
and Walter, P.
(1996)
J. Cell Biol.
134,
269-278[Abstract/Free Full Text]
|
| 48.
|
Rapoport, T. A.,
Rolls, M. M.,
and Jungnicket, B.
(1996)
Curr. Opin. Cell Biol.
8,
499-504[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Chen-Levy, Z.,
and Cleary, M. L.
(1990)
J. Biol. Chem.
265,
4929-4933[Abstract/Free Full Text]
|
| 50.
|
Lu, Y.,
Xiong, X.,
Helm, A.,
Kimani, K.,
Bragin, A.,
and Skach, W. R.
(1998)
J. Biol. Chem.
273,
568-576[Abstract/Free Full Text]
|
| 51.
|
Zhang, J. T.,
Chen, M.,
Foote, C. I.,
and Nicholson, B. J.
(1996)
Mol. Biol. Cell
7,
471-482[Abstract]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
